CA2680649A1 - Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells - Google Patents
Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells Download PDFInfo
- Publication number
- CA2680649A1 CA2680649A1 CA002680649A CA2680649A CA2680649A1 CA 2680649 A1 CA2680649 A1 CA 2680649A1 CA 002680649 A CA002680649 A CA 002680649A CA 2680649 A CA2680649 A CA 2680649A CA 2680649 A1 CA2680649 A1 CA 2680649A1
- Authority
- CA
- Canada
- Prior art keywords
- stem cells
- cells
- hematopoietic
- hematopoietic stem
- osteoclasts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0643—Osteoclasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/10—Mineral substrates
- C12N2533/18—Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.
Description
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLt1S D'UN TOME.
CECI EST LE TOME DE
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME r2 OF 2 NOTE: For additional volumes please contact the Canadian Patent Office.
SEQUENCE LISTING
<110> Osiris Therapeutics, Inc.
<120> Regulation of Hematopoietic Stem Cell.Differentiation by the Use of Human Mesenchymal Stem Cells <130> 68975-259 <140> CA 2330190 <141> 1999-06-08 <160> 8 <170> PatentIn version 3.0 <210> 1 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 1 cgatcacaat ctgcagtacc 20 <210> 2 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 2 acccagtgag tcttcagtcc 20 <210> 3 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 3 tttccagggc ttctttgtt 19 <210> 4 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 4 cttggttgtt ggctggttc 19 <210> 5 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 5 accactacta cacagacagc 20 <210> 6 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 6 aggagaccaa agacactgca 20 <210> 7 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 7 ttctatttca gagcgcagat 20 <210> 8 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 8 agtcatgttg gagatcttgg 20 DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLtJS D'UN TOME.
CECI EST LE TOME DE
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME OF _2 NOTE: For additional volumes please contact the Canadian Patent Office.
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLt1S D'UN TOME.
CECI EST LE TOME DE
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME r2 OF 2 NOTE: For additional volumes please contact the Canadian Patent Office.
SEQUENCE LISTING
<110> Osiris Therapeutics, Inc.
<120> Regulation of Hematopoietic Stem Cell.Differentiation by the Use of Human Mesenchymal Stem Cells <130> 68975-259 <140> CA 2330190 <141> 1999-06-08 <160> 8 <170> PatentIn version 3.0 <210> 1 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 1 cgatcacaat ctgcagtacc 20 <210> 2 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 2 acccagtgag tcttcagtcc 20 <210> 3 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 3 tttccagggc ttctttgtt 19 <210> 4 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 4 cttggttgtt ggctggttc 19 <210> 5 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 5 accactacta cacagacagc 20 <210> 6 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 6 aggagaccaa agacactgca 20 <210> 7 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 7 ttctatttca gagcgcagat 20 <210> 8 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: PCR Primer <400> 8 agtcatgttg gagatcttgg 20 DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLtJS D'UN TOME.
CECI EST LE TOME DE
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME OF _2 NOTE: For additional volumes please contact the Canadian Patent Office.
Claims (8)
1. A method of obtaining genetically modified osteoclasts comprising transducing hematopoietic progenitor cells with exogenous genetic material and placing the transduced hematopoietic cells under conditions suitable for differentiation of the hematopoietic stem cells into osteoclast cells which contain the exogenous genetic material.
2. The method of claim 1 wherein the hematopoietic cells are differentiated in vivo.
3. The method of claim 1 wherein the hematopoietic cells are administered in vivo with human mesenchymal stem cells.
4. A composition comprising genetically modified osteoclasts.
5. The composition of claim 4 wherein the genetically modified osteoclasts are from a non-transformed cell line.
6. A composition comprising genetically modified osteoclast precursor cells.
7. The composition of claim 6 wherein the genetically modified osteoclast precursor cells are from a non-transformed cell line.
8. A method for decreasing differentiation of hematopoietic stem cells into osteoclasts comprising co-culturing differentiating mesenchymal stem cells with hematopoietic stem cells such that osteoclastogenesis is reduced.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8843198P | 1998-06-08 | 1998-06-08 | |
US60/088,431 | 1998-06-08 | ||
US9923398P | 1998-09-04 | 1998-09-04 | |
US60/099,233 | 1998-09-04 | ||
CA002330190A CA2330190C (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002330190A Division CA2330190C (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2680649A1 true CA2680649A1 (en) | 1999-12-16 |
Family
ID=26778653
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002680649A Abandoned CA2680649A1 (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
CA002330190A Expired - Fee Related CA2330190C (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002330190A Expired - Fee Related CA2330190C (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
Country Status (12)
Country | Link |
---|---|
US (1) | US6255112B1 (en) |
EP (1) | EP1084230B1 (en) |
JP (1) | JP2003505006A (en) |
AT (1) | ATE375799T1 (en) |
AU (1) | AU4336499A (en) |
CA (2) | CA2680649A1 (en) |
CY (1) | CY1107121T1 (en) |
DE (1) | DE69937347T2 (en) |
DK (1) | DK1084230T3 (en) |
ES (1) | ES2296413T3 (en) |
PT (1) | PT1084230E (en) |
WO (1) | WO1999064565A2 (en) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021766A2 (en) * | 1999-09-23 | 2001-03-29 | Cell Science Therapeutics | Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells |
AU2002239424A1 (en) * | 2000-11-14 | 2002-05-27 | The University Of Louisville Research Foundation, Inc. | Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients |
CA2430989A1 (en) * | 2000-12-06 | 2002-06-13 | Robert J. Hariri | Method of collecting placental stem cells |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
WO2002063962A1 (en) * | 2001-02-14 | 2002-08-22 | Hariri Robert J | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
EP2316919B1 (en) | 2001-02-14 | 2015-10-07 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
CA2456607A1 (en) * | 2001-08-08 | 2003-02-20 | Schering Corporation | Uses of mammalian cytokine; related reagents |
JP2005531507A (en) * | 2002-03-02 | 2005-10-20 | ザ ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Method for local production and / or delivery of anticancer substances by stromal cell precursors |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
MXPA04011851A (en) * | 2002-05-30 | 2005-03-31 | Celgene Corp | Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes. |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
KR101042448B1 (en) | 2002-11-26 | 2011-06-16 | 안트로제네시스 코포레이션 | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
US8603462B2 (en) * | 2003-04-01 | 2013-12-10 | University Of Utah Research Foundation | Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction |
US20040209246A1 (en) * | 2003-04-15 | 2004-10-21 | Agouron Pharmaceuticals, Inc. | Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors |
EP1479760A1 (en) * | 2003-05-19 | 2004-11-24 | ProBioGen AG | Artificial immune organ |
NZ597965A (en) | 2003-10-08 | 2013-09-27 | Vet Stem Inc | Methods of preparing and using stem cell compositions and kits comprising the same |
US20050112551A1 (en) * | 2003-11-24 | 2005-05-26 | Agouron Pharmaceuticals, Inc. | Dual assay for evaluating activity and cytotoxicity of compounds in the same population of cells |
EP1799812A4 (en) | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
CA2512667A1 (en) * | 2005-01-07 | 2006-07-07 | Takahiro Ochiya | Human hepatocyte-like cells and uses thereof |
WO2006121445A2 (en) * | 2005-05-10 | 2006-11-16 | United States Of America Department Of Veteran's Affairs | Therapy of kidney diseases and multiorgan failure with mesenchymal stem cells and mesenchymal stem cell conditioned media |
NZ597304A (en) | 2005-10-13 | 2013-06-28 | Anthrogenesis Corp | Immunomodulation using placental stem cells |
US8846393B2 (en) * | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
JP5550235B2 (en) | 2005-12-29 | 2014-07-16 | アントフロゲネシス コーポレーション | Placental stem cell population |
AU2006332679A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
CA2654716A1 (en) * | 2006-06-09 | 2007-12-21 | Anthrogenesis Corporation | Placental niche and use thereof to culture stem cells |
US7993918B2 (en) * | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
KR100818213B1 (en) | 2006-09-22 | 2008-04-01 | 재단법인서울대학교산학협력재단 | Human Cord Blood Multipotent Stem Cell Having Enhanced Proliferation Ability With Osteoclast-based Niche-like Structure and Method for Preparing the Same |
US20080118477A1 (en) * | 2006-11-09 | 2008-05-22 | Rush University Medical Center | Umbilical cord mesenchymal stem cells support cord blood hematopoiesis |
JP2010518812A (en) | 2007-02-12 | 2010-06-03 | アンスロジェネシス コーポレーション | Hepatocytes and chondrocytes derived from adherent placental stem cells, and enriched cell populations of CD34 +, CD45− placental stem cells |
CN103356711A (en) | 2007-02-12 | 2013-10-23 | 人类起源公司 | Immunomodulation using placental stem cells |
US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
CN101173247B (en) * | 2007-08-08 | 2010-06-02 | 中国人民解放军军事医学科学院基础医学研究所 | Method for culturing osteoclast with mesenchyma stem cell combined with cell factor |
AU2008307633C1 (en) | 2007-09-28 | 2015-04-30 | Celularity Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
KR20180108887A (en) | 2008-08-20 | 2018-10-04 | 안트로제네시스 코포레이션 | Treatment of stroke using isolated placental cells |
JP6169316B2 (en) | 2008-08-20 | 2017-07-26 | アンスロジェネシス コーポレーション | Improved cell composition and method for producing the same |
MX2011001992A (en) | 2008-08-22 | 2011-03-29 | Anthrogenesis Corp | Methods and compositions for treatment of bone defects with placental cell populations. |
RU2562154C2 (en) | 2008-11-19 | 2015-09-10 | Антродженезис Корпорейшн | Amniotic adhesive cells |
EP2449095A1 (en) | 2009-07-02 | 2012-05-09 | Anthrogenesis Corporation | Method of producing erythrocytes without feeder cells |
EP2454362A4 (en) * | 2009-07-14 | 2013-02-27 | Massachusetts Inst Technology | Hematopoietic stromal progenitor cells and uses thereof |
JP5827220B2 (en) | 2010-01-22 | 2015-12-02 | 国立大学法人京都大学 | Method for improving the efficiency of establishment of induced pluripotent stem cells |
ES2646750T3 (en) | 2010-01-26 | 2017-12-15 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
KR20190076060A (en) | 2010-04-07 | 2019-07-01 | 안트로제네시스 코포레이션 | Angiogenesis using placental stem cells |
EP2555783A1 (en) | 2010-04-08 | 2013-02-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
WO2012009422A1 (en) | 2010-07-13 | 2012-01-19 | Anthrogenesis Corporation | Methods of generating natural killer cells |
US9725689B2 (en) | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
JP6029137B2 (en) | 2010-12-03 | 2016-11-24 | 国立大学法人京都大学 | Efficient method for establishing induced pluripotent stem cells |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
ES2707579T3 (en) | 2011-06-01 | 2019-04-04 | Celularity Inc | Pain treatment using placental cytoblast |
WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
BR112014020119A2 (en) | 2012-02-13 | 2020-10-27 | Gamida-Cell Ltd | culture of mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
CA2921948C (en) | 2013-09-04 | 2019-11-19 | Otsuka Pharmaceutical Factory, Inc. | Method for preparing pluripotent stem cells |
CN105992816B (en) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | Cell amplification in bioreactor |
JP6783143B2 (en) | 2014-03-25 | 2020-11-11 | テルモ ビーシーティー、インコーポレーテッド | Passive replenishment of medium |
CN106715676A (en) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | Scheduled feed |
KR101566450B1 (en) * | 2015-04-03 | 2015-11-05 | (유)스템메디케어 | A Method for mass production of proteins from mesenchymal stem cells |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Cell expansion |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
JP7393945B2 (en) | 2017-03-31 | 2023-12-07 | テルモ ビーシーティー、インコーポレーテッド | cell proliferation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
DE4322570C1 (en) * | 1993-07-07 | 1994-06-16 | Gsf Forschungszentrum Umwelt | Stromal cell lines from human bone marrow cells - contain SV-40 DNA with defective origin of replication, useful as feeder cells, for prodn. of growth factors and for gene expression |
US5719058A (en) * | 1995-04-10 | 1998-02-17 | Merck & Co., Inc. | Method for producing a highly enriched population of osteoclast cells |
-
1999
- 1999-06-08 DE DE69937347T patent/DE69937347T2/en not_active Expired - Lifetime
- 1999-06-08 AT AT99955496T patent/ATE375799T1/en not_active IP Right Cessation
- 1999-06-08 CA CA002680649A patent/CA2680649A1/en not_active Abandoned
- 1999-06-08 EP EP99955496A patent/EP1084230B1/en not_active Expired - Lifetime
- 1999-06-08 AU AU43364/99A patent/AU4336499A/en not_active Abandoned
- 1999-06-08 US US09/327,796 patent/US6255112B1/en not_active Expired - Lifetime
- 1999-06-08 WO PCT/US1999/012847 patent/WO1999064565A2/en active IP Right Grant
- 1999-06-08 ES ES99955496T patent/ES2296413T3/en not_active Expired - Lifetime
- 1999-06-08 DK DK99955496T patent/DK1084230T3/en active
- 1999-06-08 JP JP2000553555A patent/JP2003505006A/en active Pending
- 1999-06-08 CA CA002330190A patent/CA2330190C/en not_active Expired - Fee Related
- 1999-06-08 PT PT99955496T patent/PT1084230E/en unknown
-
2008
- 2008-01-02 CY CY20081100007T patent/CY1107121T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE69937347D1 (en) | 2007-11-29 |
WO1999064565A3 (en) | 2000-02-24 |
AU4336499A (en) | 1999-12-30 |
CA2330190A1 (en) | 1999-12-16 |
DK1084230T3 (en) | 2008-03-03 |
EP1084230A2 (en) | 2001-03-21 |
PT1084230E (en) | 2008-01-25 |
DE69937347T2 (en) | 2008-09-04 |
ATE375799T1 (en) | 2007-11-15 |
WO1999064565A9 (en) | 2000-04-13 |
CY1107121T1 (en) | 2012-10-24 |
EP1084230B1 (en) | 2007-10-17 |
ES2296413T3 (en) | 2008-04-16 |
WO1999064565A2 (en) | 1999-12-16 |
US6255112B1 (en) | 2001-07-03 |
JP2003505006A (en) | 2003-02-12 |
CA2330190C (en) | 2009-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2680649A1 (en) | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells | |
Gronthos et al. | A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells | |
Moore et al. | Stromal support enhances cell-free retroviral vector transduction of human bone marrow long-term culture-initiating cells | |
CN1416462A (en) | Techniques for growth and differentiatition of human pluripotent stem cells | |
CN108588023B (en) | Method for producing chimeric antigen receptor modified gamma delta T cells | |
KR101985271B1 (en) | Mesenchymal stem cell expressing trail and cd, and use thereof | |
CN1863904A (en) | Method of inducing the differentiation of stem cells into myocardial cells | |
Zeiter et al. | Effect of TGF β 1, BMP-2 and hydraulic pressure on chondrogenic differentiation of bovine bone marrow mesenchymal stromal cells | |
Zhang et al. | Effects of hypoxia on proliferation and osteogenic differentiation of periodontal ligament stem cells: an in vitro and in vivo study | |
WO2006017320A2 (en) | Compositions and methods for myogenesis of fat-derived stem cells expressing telomerase and myocardin | |
Ohishi et al. | Accelerated cell-cycling of hematopoietic progenitors by the flt3 ligand that is modulated by transforming growth factor-beta | |
Cheng et al. | Cell cycle entry of hematopoietic stem and progenitor cells controlled by distinct cyclin-dependent kinase inhibitors | |
Chang et al. | Phorbol myristate acetate differentiates human adipose-derived mesenchymal stem cells into functional cardiogenic cells | |
CN115558641A (en) | High-purity effector immune cell population, and culture method, reagent composition and application thereof | |
CN1630714A (en) | Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression | |
Bashyal et al. | Improving the safety of mesenchymal stem cell-based ex vivo therapy using herpes simplex virus thymidine kinase | |
KR20220097910A (en) | cell selection method | |
Kermani et al. | Differentiation capacity of mouse dental pulp stem cells into osteoblasts and osteoclasts | |
Li et al. | A comparative gene-expression analysis of CD34+ hematopoietic stem and progenitor cells grown in static and stirred culture systems | |
CN1882687A (en) | Method of growing myocardial cells | |
CN112626028B (en) | Engineering cell for activating NK-like cells and preparation method and application thereof | |
CN112592898B (en) | Reprogrammed NK feeder cells and preparation method and application thereof | |
CN113502265A (en) | Inducer for reprogramming T cells into NK-like cells and application thereof | |
CN114729324A (en) | Preparation method and application of immortalized stem cell strain | |
KR20190015154A (en) | Pharmaceutical composition for preventing or treating cancer comprising mesenchymal stem cell expressing trail and cd |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |